The Latest Cardiac and Vascular News
OAKLAND, Calif., July 17, 2019 /PRNewswire/ — Both numbers in a blood pressure reading — the “upper” systolic and the “lower” diastolic — independently predicted the risk of heart attack or stroke in a very large Kaiser Permanente study that included more than 36 million blood pressure readings from more than 1 […]
VANCOUVER, July 17, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has received written notification (the “Nasdaq […]
WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it has installed CorPath® GRX Systems in two new hospitals affiliated with one of the nation’s largest hospital networks, HCA Healthcare. The new systems are now installed in hospital locations […]
Expanded indication provides access to robotic technology in vascular procedures from head to toe July 17, 2019 06:45 AM Eastern Daylight Time WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that it received approval from the Australian Therapeutic Goods Administration […]
FREMONT, Calif., July 17, 2019 /PRNewswire/ — Q’Apel Medical announced today that it received U.S. Food and Drug Administration clearance for its novel walrus Balloon Guide Catheter (BGC). In the neurovascular space where speed, reliability and performance are so critical to patient outcomes, physicians and patients demand that innovative technologies are best-in-class. The walrus BGC, […]
SAN DIEGO, July 16, 2019 /PRNewswire/ — Ambrx Inc. today announced that Bristol-Myers Squibb Company (“BMS”) has initiated a phase I clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of long-acting Relaxin for the potential treatment of heart failure (“HF”). Long-acting Relaxin is an investigational biologic produced using Ambrx’ proprietary expanded genetic code […]
BOSTON, July 16, 2019 /PRNewswire/ — Biofourmis, a fast-growing global leader in digital therapeutics, has entered a research partnership with the Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI). Biofourmis’ mobile platform BiovitalsHFTM will be leveraged in a study of patients with heart failure to monitor functional capacity and quality of life […]
Pending U.S. Food and Drug Administration (“FDA”) Humanitarian Use Device (“HUD”) Classification and Approval as a HUD, Company Expects to Begin Commercializing Reducer in U.S. by Early 2020 A potential HUD Reducer designation for Canadian Cardiovascular Society (“CCS”) Class IV would, by statute, allow the treatment of a limited number of […]
PETAH-TIKVA, Israel, July 16, 2019 /PRNewswire/ — Leviticus Cardio today announced the appointment of Prof. Mandeep R. Mehra to its Scientific Advisory Board. “We are very excited that Prof. Mehra has joined our Scientific Advisory Board. He is recognized as one of the world’s leading cardiologists in advanced heart failure and cardiac transplantation, and he will provide immediate […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new Advanced Circulatory Support (ACS) pump and controller, the LifeSPARC system. Derived from more than 20 years of life support experience with TandemLife, LifeSPARC […]
